BIOMUNEX PHARMACEUTICALS
Description
BIOMUNEX Pharmaceuticals is a clinical-stage biopharmaceutical company based in Paris, led by an international team, focused on the discovery and development of disruptive immuno-therapeutics in oncology, thanks to its proprietary next-generation bi- and multi-specific antibody platform, the BiXAb® platform.
Biomunex is developing a disruptive biological approach, the MAIT-engagers, that engage MAIT cells to kill cancer cells, which may become a true game changer in the field of cancer immunotherapy. The BiXAb-MAIT engagers represent a novel approach of T cell engagers, that is expected to overcome the limitations of traditional CD3+ T-cell engagers, such as cytokine release syndrome (a common and potentially fatal toxicity), yield superior and durable clinical responses in solid tumors, while increasing safety and enlarging the therapeutic window. BIOMUNEX has started several BiXAb-MAIT engager programs in preclinical development for different targets and cancers.
Company members
Pierre-Emmanuel Gerard, MD, CEO; Simon Plyte, PhD, CSO
